Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis

Dena Zeraatkar, Ellen Cusano, Juan Pablo Díaz Martinez, Anila Qasim, Sophia O. Mangala, Elena Kum, Jessica J. Bartoszko, Tahira Devji, Thomas Agoritsas, Francois Lamontagne, Bram Rochwerg, Per O Vandvik, Romina Brignardello-Petersen, Reed Siemieniuk
doi: https://doi.org/10.1101/2021.07.05.21259867
Dena Zeraatkar
1Department of Biomedical Informatics, Harvard Medical School
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen Cusano
3Cumming School of Medicine, University of Calgary
Roles: internist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Pablo Díaz Martinez
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anila Qasim
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia O. Mangala
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Kum
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica J. Bartoszko
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahira Devji
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Agoritsas
2Department of Health Research Methods, Evidence, and Impact, McMaster University
12Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva
13MAGIC Evidence Ecosystem Foundation, Oslo
Roles: internist, methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francois Lamontagne
14Department of Medicine, University of Sherbooke, Sherbrooke, Quebec
15Centre de recherche du CHU University of Sherbooke, Sherbrooke, Quebec
Roles: critical care physician, methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bram Rochwerg
2Department of Health Research Methods, Evidence, and Impact, McMaster University
17Department of Medicine, McMaster University
Roles: critical care physician, methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per O Vandvik
13MAGIC Evidence Ecosystem Foundation, Oslo
19Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo
Roles: internist, methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romina Brignardello-Petersen
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reed Siemieniuk
2Department of Health Research Methods, Evidence, and Impact, McMaster University
Roles: internist, methodologist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: reed.siemieniuk{at}medportal.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To compare the effects of interleukin-6 (IL-6) receptor blockers, with or without corticosteroids, on mortality in patients with COVID-19.

Design Systematic review and network meta-analysis

Data sources WHO COVID-19 database, a comprehensive multilingual source of global covid-19 literature, and two prospective meta-analyses

Study selection Trials in which people with suspected, probable, or confirmed COVID-19 were randomized to IL-6 receptor blockers (with or without corticosteroids), corticosteroids, placebo, or standard care.

Results We assessed the risk of bias of included trials using a modification of the Cochrane risk of bias tool. We performed a Bayesian fixed effect network meta-analysis and assessed the certainty of evidence using the GRADE approach.

We identified 45 eligible trials (20,650 patients), 36 (19,350 patients) of which could be included in the network meta-analysis. 27 of 36 trials were rated at high risk of bias, primarily due to lack of blinding. Tocilizumab (20 more per 1000, 15 fewer to 59 more; low certainty) and sarilumab (11 more per 1000, 38 fewer to 55 more; low certainty) alone may not reduce the risk of death. Tocilizumab, in combination with corticosteroids, probably reduces the risk of death compared to corticosteroids alone (35 fewer per 1000, 52 fewer to 18 more; moderate certainty) and sarilumab, in combination with corticosteroids, may reduce the risk of death compared to corticosteroids alone (43 fewer, 73 fewer to 12 more; low certainty). Tocilizumab and sarilumab, both in combination with corticosteroids, may have similar effects (8 more per 1000, 20 fewer to 35 more; low certainty).

Conclusion IL-6 receptor blockers, when added to standard care that includes corticosteroids, in patients with severe or critical COVID-19, probably reduce mortality. Tocilizumab and sarilumab may have similar effectiveness.

Systematic review registration NA

What is already known on this topic?

  • IL-6 receptor blockers have immunosuppressive effects that may be important in COVID-19 patients with immune system dysfunction and inflammation

  • Corticosteroids reduce the risk of death in patients with severe or critical COVID-19

What this study adds

  • Our systematic review and network meta-analysis provides a comprehensive review of the evidence addressing the effects of IL-6 receptor blockers, alone or in combination with corticosteroids, in COVID-19

  • IL-6 receptor blockers when added to a standard care that includes corticosteroids, in patients with severe or critical COVID-19, probably reduce mortality.

  • Tocilizumab and sarilumab in combination with corticosteroids may have similar effectiveness for reducing mortality.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: This project is supported by two CIHR Operating Grants (VR4- 172738; MM1- 174897).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB exempt. All data secondary.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclaimers: None

  • Funding: This project is supported by two CIHR Operating Grants (VR4- 172738; MM1- 174897).

  • Data: Data is available in the supplementary materials.

Data Availability

All data are included in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 07, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis
Dena Zeraatkar, Ellen Cusano, Juan Pablo Díaz Martinez, Anila Qasim, Sophia O. Mangala, Elena Kum, Jessica J. Bartoszko, Tahira Devji, Thomas Agoritsas, Francois Lamontagne, Bram Rochwerg, Per O Vandvik, Romina Brignardello-Petersen, Reed Siemieniuk
medRxiv 2021.07.05.21259867; doi: https://doi.org/10.1101/2021.07.05.21259867
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Tocilizumab and sarilumab alone or in combination with corticosteroids for COVID-19: A systematic review and network meta-analysis
Dena Zeraatkar, Ellen Cusano, Juan Pablo Díaz Martinez, Anila Qasim, Sophia O. Mangala, Elena Kum, Jessica J. Bartoszko, Tahira Devji, Thomas Agoritsas, Francois Lamontagne, Bram Rochwerg, Per O Vandvik, Romina Brignardello-Petersen, Reed Siemieniuk
medRxiv 2021.07.05.21259867; doi: https://doi.org/10.1101/2021.07.05.21259867

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4901)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)